Home » USA Broker Ratings » Vertex Pharmaceuticals orpor – Consenus Indicates Potential 5.0% Upside

Vertex Pharmaceuticals orpor – Consenus Indicates Potential 5.0% Upside

Vertex Pharmaceuticals orpor with ticker code (VRTX) have now 22 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 285 and 200 with a mean TP of 232.27. Now with the previous closing price of 221.13 this is indicating there is a potential upside of 5.0%. The 50 day MA is 203.22 and the 200 day MA is 182.37. The company has a market cap of $57,578m. You can visit the company’s website by visiting: http://www.vrtx.com

Vertex Pharmaceuticals orporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals orporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies; Moderna Therapeutics; Genomics ; Merck KGaA; Darmstadt, Germany; X-Chem; Janssen Pharmaceuticals; Merck KGaA; Kymera Therapeutics; Ribometrix; and Molecular Templates The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Join us on our new LinkedIn page

Follow us on LinkedIn